Gamida Cell is a biopharmaceutical company developing advanced cell therapies for patients with blood cancers and hematologic diseases.
Gamida Cell is a biopharmaceutical company developing advanced cell therapies for patients with blood cancers and hematologic diseases. Its product includes NiCord, a cell therapy based on NAM-expanded cord blood developed to improve and extend the life-saving benefits of hematopoietic stem cell transplant. The company applies an expansion platform supporting the properties of NAM to allogeneic cell sources that include omidubicel, an investigational product with potential as a life-saving alternative for patients in need of bone marrow transplant.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
May 15, 2012 | Series E | $10M | 1 | — | — | Detail |
Sep 27, 2006 | Series D | $16M | 2 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Denali Ventures | — | Series E |
Elscint Biomedical Investment | — | Series D |